CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT between AMUNIX...License Agreement • November 4th, 2024 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made and entered into as of July 31, 2024 (the “Execution Date”) by and between Amunix Pharmaceuticals, Inc., a Delaware corporation, having corporate offices located at 2 Tower Pl #1100, South San Francisco, California, 94080 (“Sanofi”) and Vir Biotechnology, Inc., a Delaware corporation, having corporate offices located at 1800 Owens Street, Suite 900, San Francisco, CA 94158 (“Vir”). Sanofi and Vir are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Agreement No.: 75A50122C00081Other Transaction Agreement • November 4th, 2024 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
CLIN PRISMline item Title Requisition (OS) Appropriation Year CAN Object Class Amt. (Govt Share) Changed or Unchanged 0001 0001 Base Period: VIR-2482- 4002 PENNISULAPhase 2 study [***] 2022 [***] 25103 $50,000,000.00 Unchanged 0001 0001 Base Period: VIR-2482- 4002 PENNISULAPhase 2 study [***] 2022 [***] 25103 $5,000,000.00 Unchanged 0001 0001 VIR-2482-4002 PENNISULA Phase 2study [***] 2023 [***] 25106 $11,249,523.00 Unchanged 0013 0002 Option 12- FASTx VIR- 7229 [***] 2023 [***] 25106 $40,000,000.00-$35,000,000.00$5,000,000.00 Changed 0014 0003 Option 12- FASTx[***] [***] 2023 [***] 25106 $2,976,862.50 Unchanged 0014 0004 Option 12- FASTx[***] [***] 2023 [***] 25106 $7,074,015.50-$7,074,015.50$0.00 Changed Total $116,300,401.00-$42,074,015.50$74,226,385.50 Changed
Agreement No.: 75A50122C00081 BETWEENOther Transaction Agreement • November 4th, 2024 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
